Aktis Oncology, Inc. Sample Contracts
EMPLOYMENT AGREEMENTEmployment Agreement • January 5th, 2026 • Aktis Oncology, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”) is made between Aktis Oncology, Inc., a Delaware corporation (the “Company”), and Shulamit Ron-Bigger, PhD (the “Executive,” and together with the Company, the “Parties”) on December 18, 2025 and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Parties, dated August 4, 2022 (the “Prior Agreement”).
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST...Lease • December 19th, 2025 • Aktis Oncology, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made and entered into as of February 1, 2023 (“First Amendment Effective Date”), by and between IDB 17-19 DRYDOCK LIMITED PARTNERSHIP, a Delaware Limited Partnership (“Landlord”) and AKTIS ONCOLOGY, INC., a Delaware corporation (“Tenant”).
ROYALTY TRANSFER AGREEMENTRoyalty Transfer Agreement • December 19th, 2025 • Aktis Oncology, Inc. • Pharmaceutical preparations • Massachusetts
This Royalty Transfer Agreement (the “Agreement”) is effective as of August 27, 2020 (the “Effective Date”), by and between HotKnot Therapeutics, Inc., a Delaware corporation (the “Company”), MPM Oncology Charitable Foundation, Inc., a Massachusetts charitable foundation (the “MPM Charitable Foundation”) and the UBS Optimus Foundation, a Swiss charitable foundation (“Optimus,” and together with the MPM Charitable Foundation, each a “Charitable Foundation” and together the “Charitable Foundations”).
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LEASE IDB...Lease Agreement • December 19th, 2025 • Aktis Oncology, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (the “Lease”) is made and entered into as of January 13, 2022 (the “Effective Date”), by and between IDB 17-19 DRYDOCK LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), whose address is c/o Jamestown, Ponce City Market, 675 Ponce de Leon Avenue, NE, 7th Floor, Atlanta, Georgia 30308 and c/o Related Fund Management, 30 Hudson Yards, New York, New York 10001, and AKTIS ONCOLOGY, INC., a Delaware corporation, (“Tenant”) whose address is 450 Kendall Street, c/o MPM Capital, Cambridge, Massachusetts 02142. The terms set forth herein shall have the respective meanings set forth for the same in Articles I and VIII of this Lease.
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE,...License, Research and Collaboration Agreement • December 19th, 2025 • Aktis Oncology, Inc. • Pharmaceutical preparations • New York
This License, Research and Collaboration Agreement (“Agreement”) is entered into as of May 16, 2024 (the “Effective Date”) by and between Aktis Oncology, Inc., a Delaware corporation, with its principal business office at 17 Drydock Avenue, Suite 17-401, Boston, MA 02210 (“Aktis”), and Eli Lilly and Company, an Indiana corporation, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”). Lilly and Aktis are each hereafter referred to individually as a “Party” and together as the “Parties.”
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE...Exclusive License Agreement • December 19th, 2025 • Aktis Oncology, Inc. • Pharmaceutical preparations • Massachusetts
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), dated as of November 1, 2021 (the “Effective Date”), is by and between Institute for Protein Innovation, Inc. a Massachusetts nonprofit corporation with an office at 4 Black fan Circle, Boston MA 02115 (“IPI”) and Aktis Oncology Inc., a Delaware corporation, with an office at 450 Kendall Street, 5th Floor, Cambridge, MA 02142 (“Licensee”). Each of IPI and Aktis may be referred to individually as a “Party” and collectively as the “Parties”.
INDEMNIFICATION AGREEMENTIndemnification Agreement • December 19th, 2025 • Aktis Oncology, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [•] by and between Aktis Oncology, Inc., a Delaware corporation (the “Company”), and ___________ (“Indemnitee”).
Aktis Oncology, Inc. [•] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • December 19th, 2025 • Aktis Oncology, Inc. • Pharmaceutical preparations • New York
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND...Lease • March 30th, 2026 • Aktis Oncology, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made and entered into as of April 14, 2025 (the “Execution Date”), by and between IDB 17-19 DRYDOCK LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”) and AKTIS ONCOLOGY, INC., a Delaware corporation (“Tenant”).
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDED...Investors’ Rights Agreement • November 22nd, 2024 • Aktis Oncology, Inc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 20, 2024, by and among Aktis Oncology, Inc., a Delaware corporation formerly known as HotKnot Therapeutics, Inc. (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and the Key Holders (as defined below).